{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit could not be estimated due to insufficient number of participants with the event.","groupId":"OG000","lowerLimit":"10.4","upperLimit":"NA","value":"12.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"DOR: time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \\>=25% from lowest value in \\>=1 of following (serum M-protein \\[absolute increase \\>=0.5g/dL\\]; serum M-protein increase \\>=1g/dL \\[when lowest M-protein \\>=5g/dL\\]; urine M-protein \\[absolute increase \\>=200mg/24h\\]; participants without measurable serum \\& urine M-protein levels, difference between involved \\& uninvolved sFLC levels \\[absolute increase \\>10mg/dL\\]; in participants without measurable serum, urine M-protein levels \\& involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \\[absolute increase \\>=10%\\]; appearance of new lesion,\\>=50% increase from nadir in SPD of \\>1 lesion, or \\>=50% increase in longest diameter of previous lesion \\>1cm in short axis; \\>=50% increase in circulating plasma cells \\[\\>=200cells/μL\\] if this is the only measure of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"MEDIAN","populationDescription":"SAS included all enrolled participants who received at least 1 dose of study intervention. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurs first, or censoring date (maximum of 65.1 weeks of treatment)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}